Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial | Zendy

Ka Sing Wong | Zendy; Dai Yi Hu | Zendy; Abraham Oomman | Zendy; Ru San Tan | Zendy; Manesh R. Patel | Zendy; Daniel E. Singer | Zendy; Günter Breithardt | Zendy; Kenneth W. Mahaffey | Zendy; Richard C. Becker | Zendy; Robert M. Califf | Zendy; Keith A.A. Fox | Zendy; Scott D. Berkowitz | Zendy; Werner Hacke | Zendy; Graeme J. Hankey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial

Author(s) -

Ka Sing Wong,

Dai Yi Hu,

Abraham Oomman,

Ru San Tan,

Manesh R. Patel,

Daniel E. Singer,

Günter Breithardt,

Kenneth W. Mahaffey,

Richard C. Becker,

Robert M. Califf,

Keith A.A. Fox,

Scott D. Berkowitz,

Werner Hacke,

Graeme J. Hankey

Publication year - 2014

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.113.002968

Subject(s) - medicine , rivaroxaban , stroke (engine) , clinical trial , physical therapy , atrial fibrillation , warfarin , mechanical engineering , engineering

In Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial, rivaroxaban was noninferior to dose-adjusted warfarin in preventing stroke or systemic embolism among patients with nonvalvular atrial fibrillation at moderate to high stroke risk. Because of differences in patient demographics, epidemiology, and stroke risk management in East Asia, outcomes and relative effects of rivaroxaban versus warfarin were assessed to determine consistency among East Asians versus other ROCKET AF participants.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research